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Cervical  cancer  is  the  commonest  malignancy  among  women  in resource-poor  low- and middle-income
countries  (LMICs).  Western  models  of health-care  organization  and  delivery  may  not  be  suitable  for  these
settings.  Research  in  health  services  needs  to be undertaken  before  Western  oncological  prevention  and
management  protocols  can  be adopted  from  the  innovative  afﬂuent  countries.  It  is possible  to  tailoreywords:
creening
ervical cancers
eveloping countries
cervical  cancer  prevention  and  management  protocols  and  to avoid  inappropriate  technology  on the
basis  of  a literature  review  of demographic  and clinical  proﬁles  in  LMICs.
©  2013  The  Authors.  Published  by Elsevier  Ltd.  Open access under CC BY-NC-ND license.IGO  staging system
esource-constrained
ntroduction
Cervical cancer is one of the commonest malignancies and
auses of cancer death in less-developed regions of the world, with
ge-standardized incidence and mortality rates of 17.7 and 9.7
espectively. Every year, more than 80% of new cases and conse-
uent deaths occur in the developing regions of the world. With
34,420 new cervical cancer cases and 72,825 deaths reported by
LOBOCON 2008, India accounts for more than a quarter of the
lobal burden of cervical cancer [1]. A wide variation in incidence
ates and differential clinical proﬁles of cervical cancer between
ations and geographical regions suggests a role for environmental
actors in etiology, pathogenesis and progression. Human papillo-
avirus (HPV), poor genital hygiene, patterns of sexual behavior,
ultural factors, socio-economic factors (education and income),
moking, and a diet deﬁcient in vitamin A are some of the causal
ssociations and etiological risk factors of cervical cancer. Lower
ocio-economic status (SES) may  be associated with lack of aware-
ess of genital hygiene, indulgence in high-risk sexual activities
nd subsequent acquisition of sexually transmitted HPV infection,
nd development of pre-neoplastic changes (dysplasia and cer-
ical intraepithelial neoplasia grades I through III) with gradual
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Open access under CC BY-NC-ND lprogress to invasive cervical cancers (coherence of association)
[2]. HPV has occupied a central position in the etio-pathogenesis
of cervical cancer since high-risk HPV DNA is consistently identi-
ﬁed in formalin-ﬁxed parafﬁn-embedded tissue specimens, small
pre-neoplastic lesions, and also in cervical scrapes (temporal asso-
ciation and speciﬁcity of association, consistency of association)
[3]. Disruption of the E2 gene of the host caused by integration
of HPV DNA in the genome of infected subjects leads to the pro-
duction of E6 and E7. Accumulation of multiple mutations and
cervical cancer are the sequential outcomes of interference of E6
and E7 onco-proteins with the tumor suppressor function of p53
and pRB (biological plausibility) [4]. The germ theory of disease
(Koch’s postulate) insists that the cause must be both necessary
and sufﬁcient for the occurrence of the disease before it can be qual-
ify as the cause of that disease. However, the association between
HPV and cervical cancer fails to satisfy the criterion of a one-to-one
causal relationship of Koch’s postulate, as HPV is a necessary but
not a sufﬁcient cause of cervical cancer. Although HPV falls short
by the criterion of a direct causal association with cervical can-
cer, it completely fulﬁlls additional criteria for judging causality,
i.e., temporal association, strength of association (higher relative
risk of cervical cancer in HPV-infected individuals), speciﬁcity of
association (further strengthened by the discovery of HPV DNA in
malignant neoplasms elsewhere in body), consistency of associa-
tion, biological plausibility, and coherence of association, thereby
ﬁrmly establishing HPV as the major contributing factor in the
pathogenesis of cervical cancer [2].
Like any other chronic ailment, cervical cancer is also associ-
ated with many other risk factors and cofactors. These factors may
act additively or synergistically with HPV in cervical carcinogenesis
icense.
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multifactorial association). Other risk factors and cofactors per se
ay  not be carcinogenic in the absence of HPV, and HPV alone may
ot be a sufﬁcient etiological factor in transforming normal cervical
ucosa cells into atypical, dysplastic, pre-neoplastic and invasive
ervical cancer cells. Critical biochemical events of the interaction
etween HPV and other risk factors and cofactors at the cellular
evel have yet to be elucidated. Emphasis on SES improvement
ould be a major path-changer in epidemiology, public health and
linical management of cervical cancer, as SES has a bearing on
any of the risk factors and cofactors of the disease. Epidemiolog-
cal studies have demonstrated that cervical cancer incidence and
ortality reduce with the advancement of SES, i.e., afﬂuent nations
ave a lower incidence and mortality as a function of SES [2]. Almost
ll of the hungry people and one third of 870 million people living
elow the poverty line live in developing regions of the world, and
ndia may  account for >80% and >25% of the global cervical cancer
urden (incidence and mortality, respectively) [5]. Incidence and
ortality rates have an inverse relationship with socio-economic
tatus even within the conﬁnes of territorial boundaries. Incidence,
ortality from cervical cancer, and utilization of the Papanico-
aou (Pap) smear for early detection of cervical cancer differ across
ocial groups even in developed nations. For example, American
lack and Hispanic women have a higher risk of developing cervical
ancer and are more likely to die of the disease compared to Cau-
asian (white) women. American women of lower SES are also at
isk of missing annual cervical cancer screening cytological exam-
nation and consequent early detection of their genital cancers
6,7]. It is very clear from the preceding discussion that SES deter-
ines the utilization of preventive oncological services, incidence,
attern, and survival of cervical cancer in economically advanced
ountries. Lack of adequate health infrastructure, low priority for
esearch, poor documentation, absence of a population-based can-
er registry, improper implementation of programs for collection of
ancer data and statistics, corruption, social and civil disturbances
n low- and middle-income countries, sole focus on treatment of
ancer patients with very little emphasis on prevention and early
etection, concentration of cancer care resources in metros and
ity complexes, all contribute to the socio-economic difﬁculties
f people and compromise the optimum management of cervical
ancer in economically emerging nations. Unlike the West, devel-
ping countries have made very little progress in designing and
onducting research enquiring into various issues encountered by
ancer patients in accessing anticancer, supportive, palliative and
ehabilitation services. The huge burden of disease, the low bud-
etary allocation for health care, the consumption of a signiﬁcant
mount of resources in managing communicable diseases, mount-
ng social issues of gender violence, crime, corruption, an increasing
opulation, and poverty are responsible for the constantly shifting
ocus of media, policy-makers and legislators [8–11]. A multitude
f social issues are responsible for lack of attention, easy dis-
ractibility, disorganization, procrastination and forgetfulness on
he part of public health decision-makers. As a consequence, the
rowing problem of cancer and its prevention and control has not
ome under the scrutiny of media, policy-makers and legislators
n developing countries. Overloading of an already constrained
ealth-care system is the outcome of inequitable distribution of
ealth resources, and many cancer patients die in the commu-
ity because of poor access to cancer treatment facilities and the
naffordability of expensive anticancer therapy for a large major-
ty of the poor masses [12]. Western models of organization of
ealth-care systems and sophisticated prevention and manage-
ent protocols of afﬂuent nations have further worsened thecenario. Research and evaluation of prevailing health services in
he current socio-economic climate has always been overlooked or,
t the most, taken a back seat. Health-system organization, labora-
ory investigation work-up, therapy schema, follow-up protocols,ancer Policy 2 (2014) 63–73
treatment  techniques, cancer management devices and equip-
ment of socio-economically advanced countries have been adopted
without extensive subjection of cancer health services to indepen-
dent and combined pre-adoption or post-adoption evaluation for
relevance, adequacy, accessibility, acceptability, effectiveness, efﬁ-
ciency and impact [11].
Socio-economically backward regions of the world have >80%
of Earth’s population, and this may  correspond to 72.80% of the
global cases of cancer in these less developed regions [5]. Low-
and middle-income countries (LMICs) are also battling population
expansion, very low budgetary allocation for health, communica-
ble diseases, insanitation, poverty, corruption, unmet reproductive
maternal and child health needs, and lack of universal primary pre-
vention and health-care coverage. Most of the deaths in developing
countries are due to infectious diseases, and malnutrition can be
prevented by a dedicated and realistic national program. Never-
theless, infectious diseases, malnutrition and maternal and child
health continue to claim their toll in spite of the existence of a
national health program from as early as 1960s. Under-developed,
ill-prepared health-care infrastructure is far from satisfactory to
battle even the commonly prevalent and prioritized public health
issues [11]. The proportion of chronic illness and death is much
higher in higher-income countries than in LMICs. Cancer, globally,
kills more people each year than acquired immunodeﬁciency syn-
drome (AIDS), malaria and tuberculosis combined. Nevertheless,
cancer has hardly found a place in the World Health Organiza-
tion’s list of top ten causes of death, despite the colossal burden
of cancer in these economically constrained nations [13]. Another
disturbing fact is that the LMICs have to battle 80% of the global
cancer burden with just 5% of the total cancer ﬁnances [14]. The
US spent 17.8% of its GDP of approximately 15.68 trillion USD in
the year 2011 for the health care of its people, in sharp contrast
to 4.1% of 1.842 trillion USD in the year 2012 [15]. Considering
the population of the US to be roughly around one third of that
of India, the US spends around 140 times more per capita on
health care of Americans compared to that of India. Low health-care
spending of LMICs is the consequence of interplay between a num-
ber of social/economic/cultural/geopolitical factors, and nothing
explains this phenomenon better than the following. Continu-
ously expanding populations, huge dependence on life-subsistence,
lower productive traditional occupations, insufﬁcient numbers
of technical and higher educational centers to reap the beneﬁt
of economic transition and globalization, unemployment, under-
employment, a dearth of capital goods such as factories, equipment,
machinery and public utilities, ill-equipped and poorly productive
labor forces, inability to generate domestic capital or to save sub-
stantial amounts of domestic output, and corruption in the form
of capital ﬂight to tax havens in economically more advanced
countries – all these factors have critically shrunk the ﬁnancial
base of the less developed countries, thereby severely impairing
expenditure on public health care [8]. People in immediate need
of life-saving medical treatment have to resort to out-of-pocket
spending for treatment of their illness. People selling their assets
or borrowing money from money-lenders at very high interest rates
to pay for treatment of their medical conditions are well docu-
mented in India. India also has one of the highest out-of-pocket
spending on health in the world, and nearly 5% of the Indian pop-
ulation (39 million people) are pushed into poverty each year by
out-of-pocket health-care expenditure. Over the prevailing back-
ground socio-economic disadvantages, the health-care system in
India is responsible for mounting woes on already distressed fami-
lies, further disempowering people and trapping future generations
into a vicious cycle of poverty because of their health conditions
[12,16,17].
It is also very sad that most of the medical journals, irrespec-
tive of impact factor, publish articles demonstrating the superiority
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Table  1
Evaluation of health services in the context of developing countries: types of cervical cancer screening [20–22].
Relevance Adequacy Accessibility Effectiveness Efﬁciency Impact Strength Weakness Feasibility
Pap smear + − − ? + ? Early stage disease
detection
False-positive,
un-necessary
procedures,
increased  burden
on  health budget
−
Liquid-based  cytology + − − ? ? ? Same as above Same as above −
VIA/VILI  + − − ? ? Same as above,
immediate test
results  available at
the  clinic, less
resource  intensive,
as  speciﬁc as
cytology
Less  speciﬁc than
cytology,  rest are
all  same as above
−
HPV  testing and
genotyping
+  − − + ? ? Identify women at
risk  of cervical
cancer and
Lack validation −
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f the latest technical advancements over conventional practice.
lmost all of the opinions, editorials, discussions and debates
n both international and national forums, even in developing
ountries, are on the rapid adoption and implementation of these
ovel technologies and the phasing out of the well-established
obust conventional techniques, without due consideration of the
ost-effectiveness and cost-beneﬁts of the planned new techniques
nd technologies. Most of the implemented new techniques and
echnologies have not undergone rigorous behavioral and quan-
itative evaluation of their physical and clinical performances
ver a required minimum period of time. Developing countries
re not far behind in implementing the latest techniques lest
hey miss the opportunity to harness the due beneﬁts to their
ancer patients. At this point, we cannot disagree that the three-
imensional and radio-isotope imaging techniques, tumor markers
nd multi-leaf-based tele-therapy systems have increased our abil-
ty to precisely determine the disease extent, have improved the
apacity for prescribing diagnostic investigations and making bet-
er clinical decisions regarding the optimal treatment schema, and
ave decreased the visceral adverse events rates of anticancer
herapy (e.g., brain, nasal cavity, lung, breast, prostate, esophagus,
tomach, gall-bladder and retroperitoneal tumors). Improvements
n staging work-up and therapy capabilities, without doubt, have
ome from the clinical oncological practice of afﬂuent industri-
lized Western nations [18]. However, it is worthwhile to note
hat the US health-care system is criticized as being one of most
xpensive and inefﬁcient health-care systems in the world [19].
xtrapolating, simulating, adopting Western health-care preven-
ion and services delivery models without validating them in
he scenario of developing countries may  not be appropriate and
an even be counterproductive. In this context, there exists a
ire need to evolve models of health-care infrastructural orga-
ization and service delivery in LMICs. Cervical cancer being the
ommonest cancer in the developing world, as well as chronic ill-
esses that need sophisticated technology for their management,
ualiﬁes it as a subject for hypothesizing, designing, developing
nd testing alternative preventive, initial and follow-up diagnostic
ork-up, treatment schema, treatment techniques and technolo-
ies, supportive and palliative care, follow-up and rehabilitation
anagement protocols.
The  objective of this opinion/editorial is to discuss the currently
ecommended prevention efforts, initial staging baseline pre-
herapy work-up and follow-up laboratory investigations, therapy
chema, follow-up protocols, treatment techniques (especially
hose related to radiotherapy) and their clinical results, and avail-
ble devices and equipment for the treatment of cervical cancerprevalent HPV type
in  developing countries. Each of the elements of management of
cervical cancer will be described under existing components of
evaluation of cancer health services. Strengths, weaknesses and
feasibility of commonly employed cervical cancer prevention and
management methods and protocols will be deliberated in the fol-
lowing discussion under various headings (Tables 1–7).
Cervical cancer prevention program
Cervical cancer cytology (Pap smear and liquid-based cytol-
ogy), visual inspection of the cervix using acetic acid/Lugol’s iodine
(VIA/VILI), and HPV testing and genotyping are some of the preva-
lent screening techniques [20–22]. Although screening is very
useful in detecting early-stage disease and the decrease morbid-
ity and mortality, it is burdensome to health budgets of LMICs, and
the beneﬁt of screening has not been replicated in middle-income
countries [23].
Clinical  examination
Clinical  general physical and pelvic examination is the basis of
staging of cervical cancer by the FIGO (International Federation of
Gynecology and Obstetrics) staging system. The necessity of per-
forming clinical examination cannot be overstated, and it forms the
basis for staging the disease, deciding on the therapy schema, imag-
ing and therapeutic techniques and technologies, and determining
the need for additional investigations, doses of chemotherapy
and portals of radiotherapy [24]. Resource-constrained countries
should place stress on maintaining hygiene to avoid the risk of
inadvertent transmission of infections.
Baseline laboratory investigations
Laboratory investigations can be divided into hematological,
biochemical, pathological, microbiological, endoscopic, electro-
physiological, radiological, molecular imaging, and radioisotope
studies. These include hemogram, renal function test (RFT), liver
function test (LFT), random blood sugar (RBS), serum electrolyte
(SE), serology for human immunodeﬁciency virus (HIV) and hep-
atitis B surface antigen (HBsAg), chest X-ray (CXR), intravenous
pyelography (IVP), barium enema (BE), contrast-enhanced com-
puted tomography (CECT), contrast-enhanced magnetic resonance
imaging (CE-MRI), biopsy of cervical lesion, creatinine clearance
test (CCT), renal scan, electrocardiograph (ECG), echocardiography
(ECHO), multi-gated acquisition scan (MUGA), bone scan, fused
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Table 2
Evaluation of health services in the context of developing countries: types of cervical cancer screening (cont.) [20–22].
Problems in performance Alternatives Indications Contraindications Yield
Pap smear Resources intensive, highly
trained  staff to interpret the
results, need for follow-up
examination,  refusal to accept
due to modesty of women,
resources  for further
management of abnormal
screen  result may  be lacking
HPV testing and
genotyping  alone or in
combination  with
cytology
Test  every 3–5 years
for  Sexually active
women  from the age of
20–25  years
Annual screening if
abnormal  on prior
cytology
Over  65 years of age, no
prior  sexual encounter,
failure  to give consent
Sensitivity – 83%
Speciﬁcity  – 98%
PPV  – 80%
NPV  – 97.9%
Liquid-based
cytology
Same  as above HPV testing and
genotyping  alone or in
combination  with
cytology
Same  as above Same as above Sensitivity – 67–95%
Speciﬁcity  – 58–73%
VIA/VILI  Same as above Same as above Same as above Same as above Sensitivity – 70.8%
Speciﬁcity  – 95%
PPV  – 62.9%
NPV  – 96.5%
HPV  testing and
genotyping
Expensive, rest are all same as
above
Cytology screening,
visual  inspection
Same  as above Same as above Sensitivity for detecting CIN 3
or higher – 88–91%
p
a
t
c
t
s
s
p
I
i
a
l
c
m
a
u
c
s
f
y
b
s
p
a
a
C
n
s
g
c
i
i
w
a
v
c
w
p
b
o
oositron-emission tomography/computed tomography (PET-CT),
udiometry, colposcopy, cystoscopy and sigmoidoscopy. Prescrip-
ions for other investigations depend upon pre-existing co-morbid
onditions. Routine performance of hemogram, biochemical inves-
igation and cervical biopsy cannot be over-emphasized at this
tage of discussion. Cervical cancer is routinely staged by the FIGO
taging system. Staging is based on clinical pelvic examination, col-
oscopy, histopathology, CXR, IVP, cystoscopy and sigmoidoscopy.
maging and surgical staging are not included in the FIGO stag-
ng system as these investigations are not available universally,
lthough FIGO recommends documentation of these ﬁndings [24].
Hemogram and biochemistry have to be prescribed both at base-
ine, weekly, and before administering chemotherapy. Biopsy of the
ervical lesion is the basis for diagnosis of cancer; some centers
ay nevertheless start anticancer therapy based on the ﬁndings of
 clinical examination. Biopsy of cervical lesions should be insisted
pon every time to avoid exposing the patient to the toxicity of anti-
ancer therapy without any beneﬁt. CXR, IVP, BE, renal scan, bone
can, cystoscopy, sigmoidoscopy and audiometry may  be reserved
or patients with speciﬁc symptoms, as routine investigation may
ield positive ﬁndings in <10% of screened patients against the
ackground of major loss to follow-up [25]. CXR and ECG may  be
peciﬁcally requested by the anesthetist for patients undergoing
hysical pelvic examination and brachytherapy under anesthesia,
nd interstitial brachytherapy.
Developing  countries are facing an epidemic of diabetes, stroke
nd coronary artery diseases as a result of increased life expectancy.
CT and renal scan, in addition to detecting a non-functional kid-
ey due to cervical cancer, estimates glomerular ﬁltration rate and
ubsequent risk of renal failure. However, serum creatinine is the
old standard for detecting renal failure, and obsolete CCT and
ostly renal scan may  not be available in all the centers. Cisplatin
s cardiotoxic when it is part of a multi-drug chemotherapy reg-
men, and it may  not be appropriate to get ECG, ECHO, or MUGA
hen planning single-agent weekly CDDP in patients <50 years of
ge with no prior history of cardiac disease, or normotensive indi-
iduals. Further studies are needed to stratify patients at risk of
hemotherapy-induced nephrotoxicity and to identify patients in
hom cardiac evaluation can be avoided [11,26].
CECT, CE-MRI, and PET-CT are inferior with respect to detectingarametrial disease and tumors <5 mm that are best appreciated
y clinical pelvic examination. Studies demonstrating the superi-
rity of imaging over pelvic examination have failed to comment
n vaginal (particularly the lower third) and parametrial extension,Speciﬁcity for detecting CIN 3
or higher – 73–79%
i.e.,  FIGO IIIA and IIIB respectively. More than two thirds of cervi-
cal cancers are locally advanced in LMICs, and deﬁning treatment
schema and determining radiotherapy portals are based on the clin-
ical stage of the disease [27]. Therefore, three-dimensional imaging
may not be appropriate in resource-constrained countries. Imaging
also further strains already constrained health budgets, increases
waiting time for therapy, and delays the start of anticancer therapy;
as a result tumor control is decreases and there may  be an increase
in drop-out/default of patients before/during therapy respectively
[28].
Treatment schema
Surgical  techniques are basically used for diagnosis, staging
and radical resection of cervical cancer. The standard of care in
management of cervical cancer includes conization, simple hys-
terectomy for FIGO stage IA1 disease, radical hysterectomy/radical
trachelectomy with pelvic lymph-node dissection with or without
radiotherapy or radiotherapy alone for IA2, IB and IIA, chemo-
radiotherapy for locally advanced cervical cancer (IIB–IVA), and
palliative radiotherapy and/or chemotherapy for stage IVB dis-
ease. Cervical cancers are symptomatic in 70–80% of cases, and
are locally advanced by the time they present to clinicians as only
about 5% of all women  in developing countries undergo cancer
screening. Patients designated as surgical candidates for radical
curative resection form only a small fraction of the colossal burden
of cervical cancer. Moreover, comparison of primary surgery with
primary radiotherapy in a randomized controlled study of patients
with early-stage disease (IB onwards) has shown equal disease-
free and overall survival. Hence the primary focus of treatment of
cervical cancer is on radio-therapeutic management. Tele-therapy
with concurrent weekly cisplatin (CDDP) followed by intra-cavitary
(ICBT) or intra-vaginal brachytherapy (IVBT) for radical and postop-
erative treatment is the current standard of care in the management
of cervical cancer. The addition of weekly cisplatin decreases the
chances of recurrence, and increases both progression-free survival
and overall survival. Brachytherapy is an integral part of radio-
therapy management of cervical cancer as the disease control is
suboptimal in the event of brachytherapy being skipped [10,24].Treatment  techniques and technologies
Tele-therapy is usually delivered by tele-cobalt (Co-60) or linear
accelerator (linac). The International Atomic Energy Agency (IAEA)
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Table 3
Evaluation of health services in the context of developing countries: initial and follow-up diagnostic laboratory investigation [24–28].
Relevance Adequacy Accessibility Effectiveness Efﬁciency Impact Strength Weakness Feasibility
Hemogram + + − + + + Very sensitive indicator of impact of
therapy
Need  for weekly test +
RFT  + + − + + + Same as above Same as above +
LFT  + + − + + + Same as above Same as above +
RBS  + + − + + + Same as above Same as above +
SE  + + − + + + Same as above Same as above +
Serology  + + − + + + Identiﬁes virus associated malignancy Expensive +
CCT  + − − + + + Determines patients at high-risk of
chemotherapy associate renal failure
Obsolete now-a-days −
Renal  scan + − − + + ? Detects non-functioning kidney and
patients at high-risk of renal failure
Expensive −
IVP  + − − + + + Same as above Risk of contrast reaction +
CXR  + + + + + + Most basic investigation <5% of cervical cancer patients have
lung metastasis
+
BE + − − + + + In-expensive Cumbersome +
Biopsy  + − − + + + Only basis of diagnosis Time consuming and painful +
CECT  − − − − − − Can detect para-aortic lymph nodes
and hydro-ureteronephrosis
Expensive, time-consuming, may  not
truly delineate the disease extent
−
CE-MRI  − − − − − − Same as above Same as above −
ECG  Conditional+ + + + + ? Detects co-morbid conditions May  not be needed if patient is not
planned for examination and
procedure under anesthesia
+
ECHO  − − − + ? ? Same as above May  not be needed with single agent
cisplatin
MUGA − − − + ? ? Same as above Same as above −
Bone  scan − − − + ? ? Detects osteoblastic bone metastasis Cervical cancer rarely throws
metastasis  to bone
−
PET-CT − − − ? − ? Can be useful to detect
recurrent/metastatic diseases
Very expensive and its role is still
under investigation
−
Audiometry + − − + + + Determine baseline hearing level Difﬁcult to ﬁnd audiometry technicians −
Colposcopy  + − − + + + Can complement screening efforts Need technical man-power −
Cystoscopy  + − − + + + Out-patient (OPD) procedure Difﬁculty in maintaining +
Sigmoidoscopy + − − + + + Same as above Same as above +
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Table 4
Evaluation of health services in the context of developing countries: types of cervical cancer screening (cont.) [24–28].
Problems in performance Alternatives Indications
Hemogram – – Baseline and during therapy
RFT – – Same as above
LFT  – – Same as above
RBS  – – Same as above
SE  – – Same as above
Serology  – – As screening
CCT  Cumbersome RFT, renal scan Baseline
Renal  scan Available only in few centers RFT Same as above
IVP  Single non-functioning kidney is very rare RFT For FIGO staging
CXR  Exposure to radiation, waiting time Same as above
BE  Cumbersome Sigmoidoscopy Same as above
Biopsy  Basis of diagnosis
CECT  Available in very limited centers CE-MRI At the discretion of physician
CE-MRI  Same as above CECT Same as above
ECG  Before anesthesia
ECHO  Difﬁcult to access in non-metros At the discretion of physician
MUGA  Very limited availability ECHO Baseline
Bone  scan Same as above X-ray To rule out skeletal metastasis in follow-up patients with skeletal symptoms
PET-CT Same as above CECT, MRI  Recurrent/metastatic diseases
Audiometry Same as above Baseline
Colposcopy Same as above To rule out carcinoma in screen positive individuals
Cystoscopy Same as above For FIGO staging
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anel has concluded that treatment by linac is three to seven times
ore expensive than that by Co-60. Irradiation with 45 Gy to the
hole pelvis, or 40 Gy to the whole pelvis followed by another
0 Gy with mid-line shielding, is prescribed to restrict the pelvic
isceral dose to <45 Gy, i.e., the maximum tolerated dose limit
f the viscera. Most of the patients with cervical carcinoma are
reated with conventional techniques in order to reduce the cost of
reatment and waiting time. Placement of radiotherapy portal and
reatment execution is done with the help of X-ray or ﬂuoroscopy
nd Co-60 respectively. Extended-ﬁeld irradiation (EFRT) of cervi-
al cancer patients to include microscopically positive para-aortic
ymph nodes offers a marginal beneﬁt of just 1% gain in overall
urvival [29].
The  various modalities of radiotherapy currently available
or radical and palliative treatment of cervical cancer patients
nclude conventional two-/three-/four-ﬁeld techniques (Conv.RT-
/3/4), three-dimensional conformal radiotherapy (3-D CRT),
ntensity-modulated radiotherapy (IMRT), image-guided radiothe-
apy (IGRT), stereotactic body radiotherapy (SBRT) and proton
herapy (PBT). Planning radiotherapy requires imaging to decide
he radiation portals and target volume, and to delineate normal tis-
ue. One of several imaging modalities can be used for radiotherapy
lanning and dosimetry: pelvic X-ray (PXR), ﬂuoroscopy, CECT, CE-
RI  and PET-CT are the popular radiotherapy planning imaging
echniques and are sparsely scattered across the vast geographic
rea in developing countries. The X-ray-based conventional Co-60
herapy technique without the use of thermoplastic immobilization
s simple to execute, consumes minimal resources, is least labor-
nd capital-intensive, and is most popular in resource-constrained
eveloping countries. It is an extremely unfortunate situation for
ancer control in sub-Saharan African nations, as many of them lack
ven one tele-therapy unit in their country.
Brachytherapy is a means to escalate dose to primary tumor
ose – while avoiding the surrounding normal tissue (bladder,
owel and small intestine) after maximum radiation tolerance of
hese organs is reached – by placing applicators within the primary
umor. Low-dose-rate (LDR), high-dose-rate (HDR) and interstitial
rachytherapy are the different modalities of brachytherapy, and
ll have been shown to provide equal tumor control and normal
issue toxicity outcome. Arc therapy and IMRT boost are tele-
herapy techniques employed for dose escalation in cases whereSame as above
brachytherapy  is not feasible of due to lack of resources or anatom-
ical difﬁculties in placing brachytherapy applicators.
Drop-out from and default for treatment are signiﬁcant
problems with cancer patients in developing countries, so non-
compliance with treatment is quiet common. Multiple treatment
sessions of HDR brachytherapy are associated with increased
rates of drop-out, hence LDR is preferred over HDR (iridium-
192 or Co-60) in developing countries. Another disadvantage of
HDR-unit-based Ir-192 is the need to change the expensive and
labor-intensive radio-isotope every 3–6 months, in contrast to 5
years for the units based on Co-60 [30].
Supportive care
Anticancer  therapy is associated with distressing physical
symptoms, and good supportive care is an essential part of the
management of cancer patients. Supportive care increases treat-
ment compliance rate, quality of life, and survival, and improves
the patient–physician relationship while decreasing the distress
and discomfort caused by the cancer and its therapy. Pain, nau-
sea, vomiting, mucositis, cystitis, proctitis and skin exfoliation are
some of the acute adverse events of anticancer therapy. Almost
all acute adverse events can be relieved with inexpensive generic
medications [9].
Palliative  care and treatment
The  World Health Organization (WHO) analgesic step-ladder
provides around 80% pain relief among cancer patients. Medicines
falling in each step of the WHO  analgesic ladder are quite inexpen-
sive. However, strict legal restriction has hampered the availability
of many essential drugs such as oral morphine; >80% of cancer
patients in developing countries do not have access to morphine,
one of the cheapest pain-relieving medications [31]. Less than
10% of patients with cervical carcinoma present with uremia
and/or anuria. Such patients may  beneﬁt from forced diure-
sis, ureteral stenting, percutaneous nephrostomy or hemodialysis
(interventions to manage uremia). Patients with poor general
condition and those unsuitable for protracted toxic anticancer ther-
apy may  be offered short-course palliative radiotherapy. Patients
with good general condition but with persistent, recurrent and
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Table 5
Evaluation of health services in the context of developing countries: techniques and technology for radiotherapy simulation, planning and treatment delivery [24,29].
Relevance Adequacy Accessibility Effectiveness Efﬁciency Impact Strength Weakness Feasibility
Tele-therapy + − − + + + +
Weekly  CDDP + − − + + + +
ICBT  + − − + + + +
IVBT  + − − + + + +
EFRT  − − − − − − Included positive para-aortic nodes More of bowel toxicity and just 1%
survival beneﬁt
−
Conv.RT-2 + − − + + + In-expensive Access difﬁculty +
Conv.RT-3  + − − + + + Same as above Access difﬁculty, needs body
contouring
+
Conv.RT-4  + − − + + + Same as above Same as above +
3-D  CRT − − − + ? + Anatomic variation is addressed,
dosimetry is ascertained, multi-leaf
collimators reduces irradiated volume
Resource-intensive −
IMRT  − − − + ? ? Same as above Resource-intensive, increases
treatment  and waiting time
−
PBT  − − − + − ?
PXR  + − − + + + Simple, in-expensive Time-consuming +
Fluoroscopy  + − − + + + Same as above Need for dedicated machine +
CECT  − − − ? ? ? Can account for anatomic variation Resource-intensive, may  increase
waiting-time
−
CE-MRI  − − − ? ? ? Same as above Same as above −
PET-CT  − − − ? ? ? Same as above Same as above −
Immobilization − − − ? ? ? Same as above Same as above −
LDR  + − − + + + In-expensive, single-session treatment Manual brachytherapy may  expose
personnel to radiation
+
HDR  + − − + + + In-expensive, OPD treatment Multiple fraction may  lead to
treatment incompliance
+
IBRT + − − + + + Patients not suitable for ICBT Surgeon’s learning curve −
Arc  + − − ? ? ? Patients not suitable for brachytherapy Need for body contour, may  not match
the results of brachytherapy
+
IMRT  boost + − − ? ? ? Same as above Expensive, may not match the results
of brachytherapy
−
SBRT  − − − ? ? ? Same as above Same as above −
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Table 6
Evaluation of health services in the context of developing countries: supportive, palliative and follow-up care [9,25,27,28,31,32,34,35].
Relevance Adequacy Accessibility Effectiveness Efﬁciency Impact Strength Weakness Feasibility
WHO  step I + + + + + + Over-the-counter Gastric and nephrotoxic +
WHO  step II + + + + + + Same as above Nausea +
WHO  step III + − − + + + One of the cheapest drugs Strict legal regulation against narcotics +
Medication  for other
adverse-event  management
+ − − + + + Over-the-counter Available only in tertiary centers +
Interventions  to manage uremia + − − + ? ? Facilitates anti-cancer therapy Some authors are of opinion that
un-treated uremia is painless, morbid
and deteriorate QoL
+
Palliative  chemotherapy + − − ? ? ? Occasional patients may  respond and
improve QoL
Expensive and adverse events may
deteriorate QoL
+
Palliative  radiotherapy + − − + + + Short-course, improve QoL 25–40% of patients do not have access
to radiotherapy
Palliative/salvage surgery ? − − ? ? ? Patients with small central cervical
disease may  be cured
Palliative surgery is highly morbid and
deteriorate QoL
+
Best  supportive care + − − + + + Patients can be treated at local place
with in-expensive medication to
improve QoL
Many non-oncological and general
practitioners are not aware of it
+
Hospital-based  follow-up +  − + + + + Guide improvement of therapy
decision-making, provide counseling
and management of adverse events
Long-waiting time to meet specialists
and travel to cancer center may  have
resulted in lost to follow-up as high as
70%
+
Community-based follow-up + − − + + + Provides follow-up care at local place,
does not alters overall survival, time for
detection of recurrence or satisfaction
This  concept in absolutely non-existent
in  developing countries as general
practitioners are not sensitized
+
Follow-up  examination + − − + + + Early detection of local recurrence Long waiting time to meet oncologist
and lost to follow-up
+
Follow-up  investigations + − − ? ? ? Helps to rule out recurrence,
metastasis  and other non-cancer
pathology in symptomatic patients
May  have a very low or no yield if done
on asymptomatic patients
+
QoL  assessment + − − + + + Facilitates understanding of issues
faced by patients and subsequently
steer  policy-decisions
Time-consuming +
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Table 7
Evaluation of health services in the context of developing countries: health-care and welfare resources.
Relevance Adequacy Accessibility Effectiveness Efﬁciency Impact Strength Weakness Feasibility
Cancer center + − − + + + Poor access, expensive and little or no
stress on health services research
+
Radiation  oncologists + − − + + + Commercialization of health and
education has further aggravated
problem of poor access by
impoverished people in developing
countries
+
Medical  Oncologists + − − + + + Same as above +
Surgical  Oncologists + − − + + + Same as above +
Radiologists  + − − + + + Same as above +
Pathologist  + − − + + + Same as above +
Anesthetist  + − − + + + Same as above +
Physiatrist  + − − + + + Same as above +
Psychologist/Psychiatrist + − − + + + Same as above +
Radiotherapy  technologists + − − + + + Same as above +
Oncology  nurses + − − + + + Same as above +
Hospital-based MSW  + − − + + + Concentration of professionals in
metros and urban areas
+
Community-based MSW  + − − + + + Same as above +
Lodge/dormitory + − − ? ? + Decrease in-direct expenses, provide
stay in the vicinity of hospital
Un-hygiene, shortage of room forces
patients to take shelters on foot-paths
and pavements. Some patients cannot
even afford the nominal charges
+
Travel  waiver + − + + + + Reduces in-direct expenses and
improve access to therapy
Patients may be using mode of travel
other than or in addition to that which
offers travel concession. Hence the
overall scheme may  be inadequate and
may not resolve the issue for which it
is planned and implemented. i.e.
increasing access of patients to cancer
centers
+
7 al of C
m
a
Y
m
m
s
F
t
t
M
–
H
u
d
[
g
[
u
w
c
R
i
a
P
t
t
t
R
o
b
L
i
h
t
q
s
f
a
d
r
Q
l
a
P
c
d
o
o
a
p
H
c
i2 R.V. Kumar, S. Bhasker / Journ
etastatic disease can be treated with palliative chemotherapy,
nd local recurrences may  be treated with pelvic exenteration.
et another simple, cheap, widely accepted option is symptomatic
anagement of patients with advanced, persistent, recurrent and
etastatic disease for the relief of the distressing terminal illness
ymptoms (best supportive care) [32].
ollow-up
The importance of follow-up of patients who have completed
heir therapy cannot be overemphasized. There is no consensus on
he frequency of follow-up of post-therapy cervical cancer patients.
olecular imaging techniques – such as PET-CT and bone scan
 have been advocated for the detection of disease recurrence.
owever, their role in evaluating cervical cancer patients is still
nder active investigation [27]. The majority of treated patients
o not return for follow-up examination in developing countries
28]; in this setting local follow-up near the patient’s place of ori-
in may  be more appropriate without compromising the outcome
33]. Clinical physical examination may  be the mainstay of follow-
p care of patients, and laboratory studies are restricted to patients
ith symptoms to rule out recurrence, metastasis and other asso-
iated/unrelated pathologies [25,27].
ehabilitation
Cancer is a life-threatening disease and causes signiﬁcant
mpairment of the patient’s life from the time of diagnosis,
nd such impairment persists even after the illness is cured.
atients may  face practical problems (child-care, housing, ﬁnance,
ransportation, work/school), family problems (interpersonal rela-
ionships), emotional problems, and spiritual problems in addition
o physical symptoms and handicaps caused by their illness.
ehabilitation specialists and psychologists may  be available
nly rarely, and much emphasis is placed on the role played
y oncologists, paramedics and medical social workers (MSWs).
odges/dormitories for the duration of the patients’ therapy, facil-
ties for travel-charge waivers, and involvement of community
ealth workers in taking care of patients’ children are some of
he measure that can improve treatment compliance, outcome and
uality of life of patients stricken by cancer. In India, travel conces-
ions are available on intercity trains for cancer patients traveling
or their cancer treatment. It is very much justiﬁed to extend such
 concession for travel by roads, metros and local trains, not only
uring the period of active treatment and follow-up but also for the
est of the life of the debilitated cancer patient [34].
uality of life (QoL)
Assessment  of the extent of deterioration in both immediate and
ate global QoL of cancer patients owing to the cancer and its ther-
py is rarely done in resource-constrained developing countries.
atients completely cease sexual activity after the diagnosis of
ancer and pelvic radiotherapy. Sterility, loss of libido, frigidity,
yspareunia, and menopausal symptoms caused by the cessation
f endocrine functions of the female genital tract are some of the
ther QoL issues for cervical cancer survivors. QoL assessment is
n important part of the management of cervical cancer, but the
aucity of resources may  not support a QoL program [9].
ealth-care ﬁnancing of cervical cancerMany social and health welfare schemes exist in developing
ountries for the treatment of ailments free of cost for people liv-
ng below the poverty line. However, to beneﬁt from such schemesancer Policy 2 (2014) 63–73
the  presentation of an identiﬁcation card is necessary (which is
non-existent for those in need), lengthy paper work, and a signif-
icant delay in starting treatment; drop-out of patients during the
waiting period and non-compliance with therapy due to protracted
administrative procedures to obtain approval for anticancer treat-
ment from competent authorities also occur. It has been proved
beyond doubt that cervical cancer is a disease of the poor and
under-privileged, and diagnosis of cervical cancer can be comfort-
ably taken as an index of poverty. Policy makers should realize that
there is a dire need to develop a system that provides prompt treat-
ment of cervical cancer at zero cost to the patient, and to arrange
instantaneous approval of therapy without the need for identiﬁ-
cation cards and tedious paperwork after due consideration has
been given to background poverty, disadvantage imposed by a dis-
ordered health-care system, and disability caused by the disease
per se [28,30,34].
Conclusion
Cervical cancer is the commonest malignancy among women
in developing countries. Insufﬁcient health-care budget alloca-
tion, poverty and corruption are reasons for poor access to the
health-care system, and preventive health-care research, medical
education and medical statistic infrastructure are poor. Inappro-
priate planning and execution of health care and the emergence
of unrealistic preventive measures and clinical management pro-
tocols in developing countries are the consequences of lack of
capacity to conduct health-care research on individual diseases
and has resulted in the adoption of Western models of health-care
services. There is a lot of scope for avoiding resource-consuming
investigations and selectively prescribing speciﬁc investigations
based on clinical symptoms and signs. Planning appropriate
treatment techniques and technologies may  increase treatment
compliance and satisfaction and decrease the cost of therapy and
drop-out rates. Screening for cancer prevention may  not be fea-
sible in the face of resource-constraint for both screening and
subsequent management of abnormal test. Access to palliative
care, supportive care, medications and oncology manpower can
be increased by lowering regulatory restrictions, increasing public
spending and promoting health-services research.
A detection/yield rate of 15% should be used as a cut-off for pre-
scribing or avoiding investigation and deciding the management
plan, technique and technology. Yield rates of many investigations
may not reach 15% in view of the huge attrition rate of follow-
up visits. Cervical growth biopsy plus or minus CXR and ECG, the
cheapest treatment schema of cisplatin-based chemo-radiotherapy
that is provided free of cost, and inexpensive technology (Co-60
tele-therapy and brachytherapy equipment) are all that is needed
for the management of cervical cancer in developing countries.
Establishing a facility for the treatment of cervical cancer should
be the ﬁrst step of a multi-phased national cancer control program
in developing countries. Concerns about poor documentation and
incomplete staging work-up should be weighed against the absence
of a population-based cancer registry, the signiﬁcant default and
drop-out rates for anticancer therapy during the waiting period for
investigations, and the time for planning sophisticated treatment
techniques. Prevailing health scenarios in developing countries are
offering an opportunity to policy-makers and health-care profes-
sionals to stamp on the lame excuse of resource constraint and
make use of circumstances for optimal and efﬁcient treatment of
cervical cancer. It may  appear overenthusiastic to advocate the
avoidance of certain investigations and treatment techniques, but
it is worthwhile to try alternative management protocols in an
attempt to provide universal oncological care of cervical cancer
patients in resource-constrained developing countries.
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